TransCode Therapeutics (NASDAQ: RNAZ) has announced the initiation of a Phase 2a clinical trial evaluating its lead therapeutic candidate, TTX-MC138, in up to 45 colorectal cancer patients who remain circulating tumor DNA-positive following curative-intent therapy despite no radiographic evidence of disease, indicating minimal residual disease. This high-risk patient population has a significant chance of recurrence, and the trial aims to assess the biological and clinical activity of TTX-MC138 in reducing that risk.
Conducted in collaboration with Quantum Leap Healthcare Collaborative through its PRE-I-SPY clinical trial platform, the study will evaluate the efficacy of TTX-MC138, an RNA therapeutic designed to target microRNA-10b, a well-documented biomarker of metastasis. By inhibiting this microRNA, TTX-MC138 may prevent the spread of cancer cells and improve outcomes for patients with minimal residual disease.
TransCode Therapeutics is a clinical-stage company pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. The company’s lead candidate, TTX-MC138, focuses on treating metastatic tumors that overexpress microRNA-10b. In addition to TTX-MC138, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
The initiation of this trial marks a significant step forward in addressing an unmet medical need in colorectal cancer, where minimal residual disease poses a high risk of recurrence. The collaboration with Quantum Leap Healthcare Collaborative enhances the trial's design and execution, leveraging the PRE-I-SPY platform to accelerate development.
For more information about the trial, the full press release is available at https://ibn.fm/wuRri. Updates on TransCode Therapeutics can be found in the company’s newsroom at https://ibn.fm/RNAZ.
The implications of this announcement are substantial. If successful, TTX-MC138 could provide a new therapeutic option for colorectal cancer patients with minimal residual disease, potentially reducing recurrence rates and improving survival. The trial also underscores the growing importance of RNA therapeutics in oncology, particularly in targeting biomarkers that drive metastasis.
